OpenLB
Open Library of Bioscience

Developing an Online Infrastructure to Enhance Model Accessibility and Validation: The Peer Models Network.

Abstract

No abstract text available.

References

1. Sampson CJ, Arnold R, Bryan S, Clarke P, Ekins S, Hatswell A, et al. Transparency in decision modelling: what, why, who and how? Pharmacoeconomics. 2019;37(11):1355–69. https://doi.org/10.1007/s40273-019-00819-z . [DOI: 10.1007/s40273-019-00819-z]
2. Carlson JJ, Walton SM, Basu A, Chapman RH, Campbell JD, McQueen RB, et al. Achieving appropriate model transparency: challenges and potential solutions for making value-based decisions in THE United States. Pharmacoeconomics. 2019;37(11):1321–7. https://doi.org/10.1007/s40273-019-00832-2 . [DOI: 10.1007/s40273-019-00832-2]
3. Harvard S, Werker GR, Silva DS. Social, ethical, and other value judgments in health economics modelling. Soc Sci Med. 2020;253: 112975. https://doi.org/10.1016/j.socscimed.2020.112975 . [DOI: 10.1016/j.socscimed.2020.112975]
4. Elliott KC. A taxonomy of transparency in science. In: McCullagh M, editor. Canadian Journal of philosophy. Cambridge: Cambridge University Press; 2020. pp. 1–14. https://doi.org/10.1017/can.2020.21 .
5. Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB; ISPOR-SMDM Modeling Good Research Practices Task Force. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force—7. Value Health. 2012;15(6):843–50. https://doi.org/10.1016/j.jval.2012.04.012 .
6. Feenstra T, Corro-Ramos I, Hamerlijnck D, van Voorn G, Ghabri S. Four aspects affecting health economic decision models and their validation. Pharmacoeconomics. 2022;40(3):241–8. https://doi.org/10.1007/s40273-021-01110-w . [DOI: 10.1007/s40273-021-01110-w]
7. Kent S, Becker F, Feenstra T, Tran-Duy A, Schlackow I, Tew M, et al. The challenge of transparency and validation in health economic decision modelling: a view from mount hood. Pharmacoeconomics. 2019;37(11):1305–12. https://doi.org/10.1007/s40273-019-00825-1 . [DOI: 10.1007/s40273-019-00825-1]
8. Pouwels XGLV, Sampson CJ, Arnold RJG, Open Source Models Special Interest Group. Opportunities and barriers to the development and use of open source health economic models: a survey. Value Health. 2022;25(4):473–9. https://doi.org/10.1016/j.jval.2021.10.001 .
9. Sampson CJ, Wrightson T. Model registration: a call to action. Pharmacoecon Open. 2017;1(2):73–7. https://doi.org/10.1007/s41669-017-0019-2 . [DOI: 10.1007/s41669-017-0019-2]
10. Adibi A, Harvard S, Sadatsafavi M. Programmable interface for statistical & simulation models (PRISM): towards greater accessibility of clinical and healthcare decision models. https://arxiv.org/abs/2202.08358
11. Jansen JP, Incerti D, Linthicum MT. Developing open-source models for the US health system: practical experiences and challenges to date with the open-source value project. Pharmacoeconomics. 2019;37(11):1313–20. https://doi.org/10.1007/s40273-019-00827-z . [DOI: 10.1007/s40273-019-00827-z]
12. Harvard S, Werker GR. Health economists on involving patients in modeling: potential benefits, harms, and variables of interest. Pharmacoeconomics. 2021;39(7):823–33. https://doi.org/10.1007/s40273-021-01018-5 . [DOI: 10.1007/s40273-021-01018-5]
13. Staniszewska S, Hill EM, Grant R, Grove P, Porter J, Shiri T, et al. Developing a framework for public involvement in mathematical and economic modelling: bringing new dynamism to vaccination policy recommendations. Patient. 2021;14(4):435–45. https://doi.org/10.1007/s40271-020-00476-x . [DOI: 10.1007/s40271-020-00476-x]
14. Xie RZ, Malik ED, Linthicum MT, Bright JL. Putting stakeholder engagement at the center of health economic modeling for health technology assessment in the United States. Pharmacoeconomics. 2021;39(6):631–8. https://doi.org/10.1007/s40273-021-01036-3 . [DOI: 10.1007/s40273-021-01036-3]
15. Harvard S, Winsberg E, Symons J, Adibi A. Value judgments in a COVID-19 vaccination model: a case study in the need for public involvement in health-oriented modelling. Soc Sci Med. 2021;286: 114323. https://doi.org/10.1016/j.socscimed.2021.114323 . [DOI: 10.1016/j.socscimed.2021.114323]
16. Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II Good Practices Task Force. Value Health. 2022;25(1):10–31. https://doi.org/10.1016/j.jval.2021.10.008 . [DOI: 10.1016/j.jval.2021.10.008]
17. Emerson J, Bacon R, Kent A, Neumann PJ, Cohen JT. Publication of decision model source code: attitudes of health economics authors [published erratum appears in Pharmacoeconomics. 2019 Nov;37(11):1411]. Pharmacoeconomics. 2019;37(11):1409–10. https://doi.org/10.1007/s40273-019-00796-3 .
18. Global Health CEA Registry. About the clearinghouse. http://ghcearegistry.org/ghcearegistry/ Accessed 18 Apr 2022.
19. Professional Society for Health Economics and Outcomes Research (ISPOR). Open Source Models Special Interest Group. 2022. https://www.ispor.org/member-groups/special-interest-groups/open-source-models . Accessed 18 Apr 2022.

MeSH Term